ASO GROUP Ltd acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 14,152 shares of the medical instruments supplier's stock, valued at approximately $2,746,000. Becton, Dickinson and Company comprises about 1.1% of ASO GROUP Ltd's investment portfolio, making the stock its 15th biggest position.
Several other hedge funds and other institutional investors have also recently bought and sold shares of BDX. Imprint Wealth LLC acquired a new position in Becton, Dickinson and Company during the third quarter worth $25,000. Steph & Co. raised its holdings in Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 65 shares during the last quarter. Accredited Wealth Management LLC raised its holdings in Becton, Dickinson and Company by 77.8% during the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 70 shares during the last quarter. WPG Advisers LLC raised its holdings in Becton, Dickinson and Company by 64.2% during the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 61 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in Becton, Dickinson and Company during the fourth quarter worth $32,000. 86.97% of the stock is owned by institutional investors and hedge funds.
Becton, Dickinson and Company Stock Performance
Becton, Dickinson and Company stock opened at $147.40 on Friday. The firm has a market capitalization of $40.62 billion, a P/E ratio of 37.32, a PEG ratio of 10.46 and a beta of 0.22. The stock has a fifty day moving average price of $150.21 and a 200 day moving average price of $174.25. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business's quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.
Becton, Dickinson and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. Becton, Dickinson and Company's dividend payout ratio is currently 106.33%.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on BDX. Weiss Ratings cut Becton, Dickinson and Company from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday, May 11th. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an "equal weight" rating in a report on Friday, May 8th. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a report on Tuesday, April 14th. Barclays boosted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a report on Monday, May 11th. Finally, Argus cut their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating for the company in a report on Monday, March 23rd. Seven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $183.64.
Check Out Our Latest Stock Report on Becton, Dickinson and Company
Insider Transactions at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total transaction of $166,628.00. Following the transaction, the executive vice president owned 14,272 shares of the company's stock, valued at $2,161,922.56. This trade represents a 7.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,013 shares of company stock valued at $593,434 in the last three months. 0.40% of the stock is currently owned by company insiders.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Read More
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
